Daiichi Sankyo Showcases Expanding DXd ADC Portfolio in Lung Cancer at WCLC25

Daiichi Sankyo has announced new results for its DXd antibody conjugates (ADCs) in lung cancer, reflecting the company’s progress in developing future standards of care for these patients. The presentation took place during the World Congress on Lung Cancer 2025 (WCLC25), organized by the International Association for the Study of Lung Cancer (IASLC), which took place in Barcelona from September 6th to 9th.

Daiichi Sankyo unveils new trial results and ongoing studies advancing antibody-drug conjugates for lung cancer treatment

One of the highlights presented by Daiichi Sankyo was the primary analysis of the Phase 2 IDeate-Lung01 trial, which is evaluating I-DXd in patients with previously treated extensive-stage small cell lung cancer (SCLC). This work focuses on dose optimization and expansion , with the initial results being presented at the 2024 WCLC.

“The new developments we will be presenting at WCLC continue to demonstrate the potential of our ADC to become the first B7-H3-targeted antibody conjugate for patients with pre-treated extensive-stage small cell lung cancer, for whom therapeutic options beyond platinum-based chemotherapy are limited,” said Ken Takeshita, Global Head of R&D at Daiichi Sankyo. “These results, along with other important updates, reinforce the potential of our DXd ADC technology to create new therapeutic alternatives for people with cancer.”

Data from a retrospective analysis of the phase 3 TROPION-Lung01 trial on the intracranial efficacy of datopotamab deruxtecan versus docetaxel in patients with non-small cell lung cancer (NSCLC) and baseline brain metastases were also presented. Final results from the phase 2 DESTINY-Lung05 trial with trastuzumab deruxtecan in previously treated patients with HER2-mutated NSCLC were also presented.

Daiichi Sankyo’s ongoing trials with DXd ADCs

Presentations related to ongoing studies at WCLC25 reinforce Daiichi Sankyo’s research strategy to expand its portfolio of DXd ADCs in lung cancer and address unmet medical needs. These include the Phase 3 DESTINY-Lung06 trial, which is examining the efficacy and safety of a HER2-targeted ADC in combination with pembrolizumab versus standard-of-care platinum-based chemotherapy plus pembrolizumab in first-line therapy for patients with HER2-positive metastatic NSCLC and PD-L1 TPS <50%.

Additionally, early-phase trials exploring novel therapeutic strategies in lung cancer are included, such as substudy 01G of the Phase 2 KEYMAKER-U01 trial, which is evaluating patritumab deruxtecan (HER3-DXd) in combination with pembrolizumab, with or without platinum-based chemotherapy, in patients with previously untreated stage 4 NSCLC. A Phase 1b/2 trial studying the combination of I-DXd with gocataming, a DLL3-targeted T-cell activator, in patients with relapsed or refractory extensive-stage SCLC will also be announced by Daiichi Sankyo.

__

(Featured image by Aakash Dhage via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in GACETA MEDICA. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.